Evidence map›Paper›PMID 36866388›Full record

ArticleJHEP reports : innovation in hepatology2023

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.

Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07774247 (A Multicenter, Phase II Study to Evaluate the Safety and Efficacy of Atezolizumab, Bevacizumab, and Tocilizumab in Patients With Advanced Hepatocellular Carcinoma), which is not on this map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07774247 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicenter, Phase II Study to Evaluate the Safety and Efficacy of Atezolizumab, Bevacizumab, and Tocilizumab in Patients With Advanced Hepatocellular Carcinoma

TypeinterventionalSponsorCHA UniversityRan2026 to 2029Enrolled51ConditionsHepatocellular Carcinoma (HCC)ArmsAtezolizumab, Bevacizumab, Tocilizumab
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. From Theory to Practice: Which Biomarkers Are Ready for Predicting Response in Advanced HCC?Liver international : official journal of the International Association for the Study of the Liver · 2026
    Review
  8. Article
  9. Article
  10. Targeting Tumor-Associated Macrophages and Cancer-Associated Fibroblasts to Overcome Therapeutic Resistance in Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Hannah YangMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Beodeul KangMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Yeonjung HaDepartment of Gastroenterology, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Sung Hwan LeeDepartment of Surgery, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Ilhwan KimDivision of Oncology, Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Republic of Korea.
Hyeyeong KimDepartment of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
Won Suk LeeMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Gwangil KimDepartment of Pathology, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Sanghoon JungDepartment of Radiology, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Sun Young RhaYonsei Graduate School, Yonsei University College of Medicine, Seoul, Republic of Korea.
Vincent E GaillardF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Jaekyung CheonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Chan KimMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
Hong Jae ChonMedical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
CHA University Bundang Medical Center · KRYonsei University · KRInje University Haeundae Paik Hospital · KRRoche (Switzerland) · CHUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: We elucidated the clinical and immunologic implications of serum IL-6 levels in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Ate/Bev). Methods: We prospectively enrolled 165 patients with unresectable HCC (discovery cohort: 84 patients from three centres; validation cohort: 81 patients from one centre). Baseline blood samples were analysed using a flow cytometric bead array. The tumour immune microenvironment was analysed using RNA sequencing. Results: In the discovery cohort, clinical benefit 6 months (CB Conclusions: High baseline IL-6 levels can be associated with poor clinical outcomes and impaired T-cell function in patients with unresectable HCC after Ate/Bev treatment. Impact and implications: Although patients with hepatocellular carcinoma who respond to treatment with atezolizumab and bevacizumab exhibit favourable clinical outcomes, a fraction of these still experience primary resistance. We found that high baseline serum levels of IL-6 correlate with poor clinical outcomes and impaired T-cell response in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Indexed as

AFP, alpha-foetoproteinAte/Bev, atezolizumab and bevacizumabAtezolizumabBCLC, Barcelona Clinic Liver CancerBevacizumabCB6m, clinical benefit 6 monthsCONSORT, Consolidated Standards of Reporting TrialsCRAFITY, C-reactive protein and AFP in immunotherapyCR, complete responseCTLA-4, cytotoxic T-lymphocyte-associated protein 4DC, dendritic cellECOG, Eastern Cooperative Oncology GroupFFPE, formalin-fixed paraffin-embeddedHCC, hepatocellular carcinomaHepatocellular carcinomaHR, hazard ratioIFN-γ, interferon-γIL-6ImmunotherapyMDSC, myeloid-derived suppressor cellMSI, microsatellite instabilityMVI, macrovascular invasionORR, objective response rateOS, overall survivalPBMC, peripheral blood mononuclear cellPD-1, programmed-death-1PD-L1, programmed-death ligand-1PD, progressive diseasePFS, progression-free survivalPR, partial responseRECIST, Response Evaluation Criteria in Solid TumoursSD, stable diseaseTME, tumour microenvironmentTNF-α, tumour necrosis factor-αVEGF, vascular endothelial growth factor

Identifiers

PMID36866388
PMCPMC9972403
OpenAlexW4316506182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.